Introduction {#Sec1}
============

Typical antipsychotics such as haloperidol and pimozide have been prescribed to control tic symptoms as first-line agent \[[@CR1]\]. More recently, clinical experience with atypical neuroleptics have increased owing to the efficacy and the more tolerable adverse effects relative to some classical antipsychotics \[[@CR1]--[@CR11]\]. Some drugs such as risperidone \[[@CR7], [@CR12]\], quetiapine \[[@CR13]\], and olanzapine \[[@CR4], [@CR10], [@CR11]\], however, may cause unwanted metabolic side effects, which may worsen patient quality of life as well as general medical health status.

Aripiprazole is another candidate atypical antipsychotic agent for patients with tic disorders. This drug has a lower risk of metabolic side effects than other atypical neuroleptics. In addition, aripiprazole has a unique pharmacodynamic property, namely dopamine partial agonist activity \[[@CR14]\]. Because abnormalities in the brain dopamine system may be closely related to the pathology of tic disorders \[[@CR15]\], we hypothesized that aripiprazole may have therapeutic effects on tic manifestations. Several clinical trials, including our previous studies, have revealed that aripiprazole may be successful in treating patients with tic disorders, due to its high efficacy and tolerability \[[@CR16]--[@CR24]\]. No study to date, however, has compared the efficacy and tolerability of aripiprazole and typical antipsychotics in these patients. We therefore compared the efficacy and tolerability of aripprazole with haloperidol, a typical antipsychotic agent widely used to treat children and adolescents with tic disorders.

Methods {#Sec2}
=======

Participant characteristics {#Sec3}
---------------------------

Forty-eight children and adolescents with tic disorders (33 males, 15 females; mean ± SD age = 10.3 ± 3.5 years; range, 6--15 years) were recruited at an outpatient clinic at a general hospital in Seoul, South Korea, from August 2005 to March 2007. Before determining eligibility, we obtained informed consent and assent from both the study subject and the child's primary caregiver. The study protocol was approved by our local Institutional Review Board.

Patients were deemed eligible if they had DSM-IV diagnosis of tic disorders, as described in the Korean version of the Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version (KSADS-PL \[[@CR25]\]) and Total Tic scores ≥22 on the Korean version of the yale global tic severity scale (YGTSS \[[@CR26], [@CR27]\]), corresponding to at least moderate tic severity. Each patient was subsequently examined by a board-certified child psychiatrist.

Exclusion criteria included current mood disorders, psychotic symptoms, and anxiety disorders, except for obsessive--compulsive disorder, the most common comorbid anxiety disorder in tic patients. Subjects with an IQ ≤ 70 on the Korean version of the Wechsler Intelligence Scale for Children-Revised (WISC-R \[[@CR28]\]) were also excluded, as were patients with previous or current seizure episodes, electroencephalogram (EEG) abnormalities, and those who had used aripiprazole previously. Subjects who had taken psychotropic medications must have been drug-free for at least 2 weeks before study entry and had to be devoid of any significant medical problems.

Study design {#Sec4}
------------

This was an open, non-randomized, parallel-group clinical trial. All subjects were evaluated at baseline by routine laboratory tests, electrocardiogram (ECG), resting pulse rate and blood pressure while sitting, height and weight measurement, medical history, and physical and neurological examinations. Choice of treatment was based on patient's preference. Patients in the aripiprazole group started at a dose of 5.0 mg/d, which was increased in 5.0--10.0 mg/d increments every 2 weeks as tolerated \[[@CR23], [@CR24]\]. Doses were reduced in 2.5--5.0 mg/d steps when intolerable side effects emerged. The maximum allowable dose was 20 mg/d and patients were treated for 8 weeks. Patients in the haloperidol group were started at a dose of 0.75 mg/d and increased in 1.5--3.0 mg/day increments every 2 weeks to a maximum tolerated dose of 4.5 mg/d \[[@CR29]\]. Psychotropic drugs to control comorbid psychiatric symptoms were not prescribed during the study period. Patients were assessed every other week, with the final assessment 8 weeks after the start of study medications.

Measurements {#Sec5}
------------

The YGTSS is a semi-structured clinical interview designed to assess current tic severity; this scale yields three summary scores; total motor (0--25), total phonic (0--25), and total tic (sum of motor and phonic) scores. The YGTTS also contains an impairment scale (0--50), which evaluates the global level of functional impairment arising from tics \[[@CR27]\]. Because this study was designed to compare efficacy in reducing tic symptoms, the primary outcome measure was total tic score. The YGTSS was administered to each subject at each visit.

Secondary outcome measures included the Clinical Global Impressions-Improvement scale (CGI-I \[[@CR30]\]), and the CGI-Severity of Illness scale (CGI-S \[[@CR31]\]). Scores of 1 (very much improved) or 2 (much improved) in the CGI-I were regarded as positive responses. Both of these tests were administered at every visit.

Adverse effects associated with these drugs were assessed using an in-house adverse effect checklist, which included the most commonly encountered side effects of aripiprazole and haloperidol, as well as general questions on health issues, current illnesses or injuries, and concomitant medical treatments. The Extrapyramidal Symptom (EPS) Rating Scale (ESRS) was also used to rate the severity of Parkinsonism, akathisia, dystonia, and dyskinesia \[[@CR32]\]. We measured height and weight at every visit. At the study endpoint, physical and neurological examinations, laboratory tests, and ECG assessments were repeated.

All tests were admitted by a single psychiatrist, who was blinded to dose changes but not to the drug of choice.

Statistical analyses {#Sec6}
--------------------

We used intent-to-treat analyses, based on patients assessed at least once after baseline. Multiple linear regression and generalized estimation equation (GEE) regression modeling were used to identify medication efficacy and the significance of changes in ESRS scores. Age, gender, duration of illness, and baseline scores of each outcome were covariates for each analysis. Fisher's exact test and the Mann--Whitney *U* test were used as appropriate for between-group comparisons. All analyses were two-sided, with statistical significance defined at an α level of 0.05.

Results {#Sec7}
=======

Participant characteristics {#Sec8}
---------------------------

Of the 48 children and adolescents with tic disorders, 31 were prescribed aripiprazole and 17 were prescribed haloperidol. Twenty-six patients (54.1%) had Tourette's disorder and 11 (21.9%) had chronic motor and vocal tic disorders. Eighteen participants (37.5%) had other comorbid psychiatric disorders, the most common being attention-deficit hyperactivity disorder (31.3%). The mean duration of illness was 3.0 ± 2.7 years and 18 subjects (37.5%) had a history of previous medication to control tic symptoms.

Although gender ratio, total IQ, type of tic disorders, comorbid conditions, duration of illness, and study medications did not differ between the two groups, the mean age was significantly higher in the aripiprazole than in the haloperidol group (11.2 ± 3.5 years vs. 8.6 ± 2.9 years; *Z* = 2.68, *p* \< 0.01). The mean dose and duration of aripiprazole were 10.6 ± 5.2 mg/d and 51.7 ± 12.6 d, respectively, whereas the mean dose and duration of haloperidol were 1.9 ± 1.1 mg/d and 46.3 ± 15.8 d, respectively (Table [1](#Tab1){ref-type="table"}).Table 1Demographic and clinical characteristics of the 48 children and adolescents with tic disordersAripiprazole group (*n* = 31)Haloperidol group (*n* = 17)Male, *n* (%)22 (71.0)11 (64.7)Age mean^a^ (SD), years11.2 (3.5) (range: 6--18)8.6 (2.9) (range: 6--16)Total IQ108.2 ± 12.4105.5 ± 9.1Type of tic disorders Tourette's disorder, *n* (%)19 (61.3)7 (41.2) Chronic motor and vocal tic disorder, *n* (%)7 (22.6)4 (23.5) Transient tic disorder, *n* (%)5 (16.1)6 (35.3)Comorbidities Attention deficit hyperactivity disorder, *n* (%)9 (29.0)6 (35.3) Oppositional defiant disorder, *n* (%)2 (6.5)0 (0) Obsessive compulsive disorder, *n* (%)3 (9.7)0 (0)Duration of tic disorders mean (SD), years3.4 (2.9)2.3 (2.3)Dose/day mean (SD), mg10.6 (5.2) (range: 2.5--20.0)1.9 (1.1) (range: 0.75--4.5)Duration of study medication mean (SD), days51.7 (12.6) (range: 14--60)46.3 (15.8) (range: 15--61)^a^*p* \< 0.01 by the Mann--Whitney *U* Test*IQ* intelligence quotient

Efficacy of aripiprazole and haloperidol: yale global tic severity scale {#Sec9}
------------------------------------------------------------------------

At baseline and at each follow-up visit, there were no significant between-group differences in tic scores, indicating that these two drugs were similarly efficacious in reducing tic symptoms (Table [2](#Tab2){ref-type="table"}). After 8 weeks of treatment, 54.3% of the aripiprazole and 63.4% of the haloperidol group showed reductions in total tic scores. Total tic score decreased over time in both groups (*Z* = −9.60, *p* \< 0.001) (Table [2](#Tab2){ref-type="table"}). This reduction was particularly marked at the first follow-up visit (week 2) in both groups (*p* \< 0.001) and was sustained throughout the study period (Fig. [1](#Fig1){ref-type="fig"}a). There were no significant between-group effects or interactions.Table 2Efficacy of aripiprazole and haloperidol in the treatment of tic disordersOutcome measuresAripiprazole group (*n* = 31)Haloperidol group (*n* = 17)Statistical value^a^Baseline8 weeksBaseline8 weeksGroup effectTime effectGroup × time Interaction effect*zpzpzp*YGTSS mean (SD) Motor tic scores17.5 (5.3)8.0 (4.4)20.5 (3.1)8.5 (6.7)−1.210.227−8.29\<0.0010.610.540 Phonic tic scores9.0 (6.7)4.5 (4.6)7.1 (8.3)2.4 (4.3)0.990.320−5.59\<0.0011.130.258 Total  tic scores26.5 (4.9)12.1 (6.4)27.6 (7.3)10.1 (7.5)−0.610.543−9.60\<0.0011.280.201CGI-I, *n* (%)^b^ Very much improved--9 (34.6)--5 (45.5)-------- Much improved--13 (50.0)--5 (45.5) Minimally improved--3 (16.7)--0 (0) No change--1 (3.8)--1 (9.1) Minimally aggravated--0--0 Much aggravated--0--0CGI-S, *n* (%) Normal, not Ill02 (7.7)01 (9.1)−0.940.35−8.83\<0.0010.690.490 Minimally ill08 (30.7)06 (54.5) Mildly ill010 (38.5)03 (27.3) Moderately ill4 (12.9)3 (11.5)1 (20.0)0 Markedly ill12 (38.7)3 (11.5)7 (36.9)0 Severely ill15 (48.4)09 (37.5)1 (9.1) Extremely severely ill0000^a^To examine the group and time effects for each outcome variable, generalized estimation equation (GEE) modeling was adopted, with age, gender, duration of illness, and baseline scores for each outcome variable included as covariates^b^Calculating patients who dropped-out*YGTSS* yale global tic severity scale, *CGI*-*I* clinical global impression-improvement, *CGI*-*S* clinical global impression-severity of illnessFig. 1**a** Percentage changes in total tic scores over time in the aripiprazole and haloperidol treatment groups. **b** Percentage changes in motor tic scores over time in the aripiprazole and haloperidol treatment groups. **c** Percentage changes in phonic tic scores over time in the aripiprazole and haloperidol treatment groups *The error bars* refer to standard deviation

At baseline, the mean motor tic score was higher in the haloperidol than in the aripiprazole group (20.5 ± 3.1 vs. 17.5 ± 5.3; *Z* = −1.87, *p* = 0.06), but the difference did not reach statistical significance. Aripiprazole reduced motor tic scores 54.3% and phonic tic scores 50.0%, whereas haloperidol reduced these scores by 58.5 and 66.2%, respectively. Motor (*Z* = −8.29, *p* \< 0.001) and phonic (*Z* = −5.59, *p* \< 0.001) tic scores decreased over time in both groups (Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}b, c), but there were no significant between-group effects or interaction terms.

Efficacy of aripiprazole and haloperidol: clinical global impression {#Sec10}
--------------------------------------------------------------------

The CGI-S scores of both groups decreased over time (*Z* = −8.83, *p* \< 0.001) without group or interaction effects. Twenty-two children and adolescents (71.0%) in the aripiprazole group and ten (58.8%) in the haloperidol group were "much improved" or "very much improved" on the CGI-I measurement after 8 weeks of medication.

Dropout rate {#Sec11}
------------

Although 25 children and adolescents in the aripiprazole group (80.6%) experienced one or more unwanted side effects, only five (16.1%) patients in this group discontinued medication prematurely owing to intolerability. In contrast, all 17 subjects in the haloperidol group experienced unexpected side effects and 6 (35.3%) were not able to continue medication owing to unbearable adverse events. Although frequencies of side effects between two groups during study period were not different (χ^2^ = 2.08, *p* = 0.15), rates of drug discontinuation were lower in the aripiprazole group relative to the haloperidol group (χ^2^ = 7.17, *p* = 0.007). The major intolerable side effects included nausea (2 patients), headache (2 patients) and sedation (1 patient) in the aripiprazole group, and sedation (4 patients) and headache (2 patients) in the haloperidol group.

Extrapyramidal symptom rating scale {#Sec12}
-----------------------------------

The total ESRS score at study endpoint was higher in the haloperidol than in the aripiprazole group. There were interaction effects between groups and a time effect of the total ESRS score (*Z* = −2.17, *p* = 0.03). Total ESRS scores did not change significantly in the aripiprazole group between 2 and 4 weeks (1.1 ± 1.7 and 1.1 ± 1.8, respectively), but increased significantly in the haloperidol group between 2 and 4 weeks (1.4 ± 2.1 and 2.8 ± 2.6, respectively); these interaction effects were statistically significant (*Z* = −2.083, *p* = 0.037) (Fig. [2](#Fig2){ref-type="fig"}). In addition, the subscale scores for Parkinsonism, akathisia and, dystonia were higher in the haloperidol group at 8 weeks. The Parkinsonism subscale of the ESRS showed an interaction effect between group and time *Z* = −2.06, *p* = 0.04). No subjects experienced dyskinesia in this study (Table [3](#Tab3){ref-type="table"}).Fig. 2Changes in ESRS scores over time in the aripiprazole and haloperidol treatment groups. *AbbreviationsESRS* extrapyramidal symptom rating scale. *The error bars* refer to standard deviationTable 3Extrapyramidal symptom rating scale scores at study endpoint in the aripiprazole and haloperidol groupsExtrapyramidal symptom rating scale scores mean (SD)Aripiprazole groupHaloperidol groupStatistical value^a^Group effectTime effectGroup ×  time interaction effect*zpzpzp*Parkinsonism0.58 (1.06)1.91 (1.92)−0.100.922.330.02−2.060.04Akathisia0.04 (0.20)0.36 (0.67)0.590.561.660.10−1.760.08Dystonia0.04 (0.20)0.36 (0.67)−0.670.50−0.050.96−0.440.66Dyskinesia0.00 (0.00)0.00 (0.00)Total0.68 (1.25)2.64 (2.77)−0.001.002.170.03−2.170.03^a^Group and time effects on the adverse effect outcome variables were evaluated using generalized estimation equation (GEE) modeling, with age, gender, duration of illness, and baseline scores for each outcome variable included as covariates

General adverse events {#Sec13}
----------------------

The most common side effects of aripiprazole were hypersomnia (58.1%), nausea/vomiting (29.0%), EPS (19.4%), and headache (16.1%), whereas the most common side effects of haloperidol included hypersomnia (82.4%), headache (58.8%), EPS (41.2%), nausea/vomiting (23.5%), gastrointestinal disturbances (11.8%), emotional hypersensitivity (11.8%), dizziness (11.8%), and chest discomfort (11.8%) (Table [4](#Tab4){ref-type="table"}). Hypersomnia (χ^2^ = 4.17, *p* = 0.04), EPS (χ^2^ = 7.84, *p* = 0.005), and headache (χ^2^ = 24.34, *p* \< 0.001) were observed less frequently in the aripiprazole group. All laboratory results before, during and after treatment were within normal limits. Any abnormalities in the results of the ECGs including QTc changes were observed before and after treatment. Between baseline and 8 weeks, the mean body weight of the subjects in the aripiprazole and haloperidol groups increased 0.16 kg/week and 0.21 kg/week, respectively, but these increases did not differ between the two groups (Mann--Whitney *U* test, *Z* = 0.291, *p* = 0.771).Table 4Adverse effects of aripiprazole and haloperidol in the current study*n* (%)Adverse eventsAripiprazole (*n* = 31)Haloperidol (*n* = 17)Hypersomnia18 (58.1)14 (82.3)Nausea/vomiting9 (29.0)4 (23.5)Extrapyramidal symptoms6 (19.4)7 (41.2)Headache5 (16.1)10 (58.8)GI disturbances2 (6.5)2 (11.8)Dry mouth2 (6.5)2 (11.8)Emotional hypersensitivity1 (3.2)2 (11.8)Dizziness1 (3.2)2 (11.8)Chest discomfort1 (3.2)2 (11.8)Anorexia1 (3.2)2 (11.8)Nocturia1 (3.2)1 (5.9)Increased appetite1 (3.2)1 (5.9)Insomnia1 (3.2)2 (11.8)Nightmare1 (3.2)1 (5.9)Polydipsia1 (3.2)0Blurred vision1 (3.2)0Joint pain02 (11.8)Febrile sense01 (5.9)School refusal01 (5.9)

Discussion {#Sec14}
==========

To our knowledge, this study is the first to directly compare the efficacy and tolerability of aripiprazole and haloperidol in the treatment of children and adolescents with tic disorders. We found that aripiprazole was as effective as haloperidol in reducing tic symptoms, as well as being better tolerated. The mean dose of aripiprazole used in this study, 10.6 mg/d, was similar to that used in our previous studies in which children and adolescents with tic disorders were treated with aripiprazole \[[@CR16], [@CR23], [@CR24]\], and to doses used in previous studies of youths with developmental disabilities \[[@CR33]--[@CR35]\], delusional disorder \[[@CR36]\], and bipolar disorders \[[@CR37]\]. In contrast, higher doses of aripiprazole have been used to treat children and adolescents with bipolar disorders \[[@CR38], [@CR39]\], catatonia \[[@CR40]\], and generalized anxiety disorder \[[@CR41]\], as well as in psychiatric inpatients \[[@CR42]\]. The aripiprazole dose used in this study was lower than that used in adults with Tourette disorder \[[@CR21], [@CR43]--[@CR45]\].

Although various atypical antipsychotics are widely used to treat tic disorders, they had weaker efficacy than typical neuroleptics such as haloperidol and pimozide, which can decrease tic symptoms by more than 60% \[[@CR29]\]. Even the first atypical antipsychotic, clozapine, was not able to sufficiently abate tic symptoms \[[@CR5]\]. Although olanzapine showed considerable efficacy, its adverse effects, such as weight gain and sedation, limits its use for tic control \[[@CR4], [@CR10]\]. Uses of quetiapine have been reported in several case reports \[[@CR12], [@CR46]--[@CR49]\] and open-label trials \[[@CR13], [@CR49]\] to decrease tic symptoms. However, in two open-label trials testing quetiapine as an anti-tic drug in children and adolescents with Tourette disorder, its efficacy and tolerability were questionable. Risperidone is one of the most widely used and best-studied atypical antipsychotics in the treatment of tic symptoms. Although relatively safe and effective in tic reduction, risperidone diminishes tic symptoms by less than 36% \[[@CR3], [@CR6]--[@CR9], [@CR50], [@CR51]\]. A double-blind, randomized trial on the efficacy of ziprasidone in reducing tic symptoms showed that it reduced tic symptoms by 35%, although side effects, most of which were tolerable, developed in more than 80% of patients \[[@CR52]\].

Aripiprazole may be more potent than other atypical antipsychotics, reducing tic symptoms by 40--53% \[[@CR23], [@CR24]\]. Aripiprazole was also found to be effective in treating antipsychotic-resistant patients with Tourette disorder \[[@CR19], [@CR21]\]. In the current study, 15 subjects (48.4%) in the aripiprazole group and 3 (17.6%) in the haloperidol group had histories of previous ineffective treatment with antipsychotic medication; nevertheless, the efficacy of aripiprazole was equivalent to that of haloperidol, suggesting that aripiprazole may be a drug of choice for drug-resistant tic patients, although further confirmation is required.

In our previous report, aripiprazole was effective at its initial dose, 5 mg, with 62.0% of the total reduction in Total Tic Score attained within 2 weeks after the start of treatment \[[@CR24]\]. Although we found that tic severity in the aripiprazole group diminished almost linearly from 2 to 8 weeks, the reduction during the first 2 weeks, during treatment with the initial dose of 5 mg/day, accounted for 60.0% of the total reduction in Total Tic Score, observed in this study. This indicates that aripiprazole may be useful in the treatment of children and adolescents with tic disorders, especially those with unbearable or strongly dysfunctional tic symptoms who need prompt symptom improvement.

More than 80% of youths taking aripiprazole experienced one or more unwanted side effects. This high incidence may have been due to the starting dose of 5 mg, which may be too high in children and adolescents with tic disorders. Nineteen subjects (61.3%) in the aripiprazole group experienced side effects after their first dose, with the side effects experienced by four patients (21.1%) disappearing spontaneously without any management or dose reduction at the next visit. Further clinical studies using lower initial doses of aripiprazole are required to confirm this possibility.

In addition to the higher dropout rate seen in the haloperidol group, the rate of EPS during the 4 weeks after starting treatment was higher in the haloperidol than in the aripiprazole group. This may be associated with differences in receptor profiles of the two drugs. Haloperidol has a strong antagonistic affinity to dopamine 2 receptors in the nigrostriatal dopamine pathway, causing EPS \[[@CR53]\], whereas aripiprazole has partial agonistic activity at the postsynaptic dopamine 2 receptors, reducing EPS development \[[@CR14]\].

Aripiprazole may be a more ideal anti-tic drug owing to its unique pharmacodynamic profile, including both antagonistic and agonistic dopamine activities, depending on the environment of the local dopamine system \[[@CR14], [@CR54]\]. This activity is strongly associated with the pathological mechanism of tic disorders. Dopamine receptor hypersensitivity may be an underlying pathology of tic disorders \[[@CR15]\]. Although several studies have confirmed the supersensitivity of the dopamine system in tic disorders, these studies did not consider the anti-dopaminergic drug effects \[[@CR55]--[@CR57]\], and several neuroimaging studies assessing influences of drugs on the dopamine system have yielded conflicting results \[[@CR58]--[@CR60]\]. Significantly, pergolide, a typical dopamine agonist, reduced tic symptoms in two previous randomized, controlled clinical studies \[[@CR61], [@CR62]\]. Thus, an imbalance in dopamine systems may be a pivotal cause of tic disorders. The stabilizing action of aripiprazole in an environment of unbalanced dopamine status, therefore, as in tic-affected brain areas, may be more ideal in abating tic symptoms.

Apart from acting as a partial dopamine agonist, aripiprazole has serotonin 2A antagonistic properties, which may also facilitate its ability to stabilize the dopamine system by increasing dopamine release \[[@CR63]\]. The serotonin 2A receptor has been associated with tic symptoms, both in animals \[[@CR64]\] and humans \[[@CR65]\]. In addition, the partial agonistic actions of aripiprazole at the serotonin 1A receptor might improve tic symptoms by decreasing anxiety \[[@CR66]\], which occurs frequently in patients with tic disorders and has been associated with tic aggravation \[[@CR1]\]. Moreover, the partial agonistic activities of aripiprazole on the dopamine 3 and 4 receptors may be correlated with the effects of this drug on tic disorders, as shown both clinically \[[@CR61], [@CR62]\] and genetically \[[@CR67]--[@CR69]\].

Although our findings indicate that aripiprazole has equivalent efficacy but higher tolerability than haloperidol in children and adolescents with tic disorders, our study had several limitations, including the small sample size, open-label approach, and short-term nature of the study. Thus, we cannot confirm the tolerability and long-term efficacy of aripiprazole in these patients. In addition, because the patients chose aripiprazole or haloperidol, it could result in differences such as age and baseline scores among the groups of patients. Double-blind, placebo-controlled, and randomized trials should be performed to overcome these limitations and determine whether aripiprazole improves tic symptoms or if our findings reflect the natural progression of tic disorders.

Conclusions {#Sec15}
===========

Our findings indicate that aripiprazole may be effective and tolerable in the treatment of children and adolescents with tic disorders. Additional controlled studies are needed to determine the efficacy and tolerability of aripiprazole in patients with tic disorders.
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